Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Granules India Ltd, Sapphire Foods India Ltd, New India Assurance Company Ltd, Craftsman Automation Ltd are among the other stocks to see a surge in volumes on BSE today, 31 August 2026.
Concord Biotech Ltd registered volume of 21.09 lakh shares by 10:46 IST on BSE, a 127.52 fold spurt over two-week average daily volume of 16536 shares. The stock slipped 0.90% to Rs.1,468.90. Volumes stood at 9482 shares in the last session.
Granules India Ltd registered volume of 5.13 lakh shares by 10:46 IST on BSE, a 29.73 fold spurt over two-week average daily volume of 17264 shares. The stock slipped 1.45% to Rs.824.85. Volumes stood at 21729 shares in the last session.
Sapphire Foods India Ltd saw volume of 8.41 lakh shares by 10:46 IST on BSE, a 6.82 fold spurt over two-week average daily volume of 1.23 lakh shares. The stock dropped 3.61% to Rs.224.00. Volumes stood at 26878 shares in the last session.
New India Assurance Company Ltd recorded volume of 9.3 lakh shares by 10:46 IST on BSE, a 6.38 times surge over two-week average daily volume of 1.46 lakh shares. The stock gained 6.04% to Rs.197.65. Volumes stood at 2.2 lakh shares in the last session.
Craftsman Automation Ltd notched up volume of 9925 shares by 10:46 IST on BSE, a 6.32 fold spurt over two-week average daily volume of 1571 shares. The stock slipped 1.15% to Rs.10,999.95. Volumes stood at 1657 shares in the last session.
The inspection took place from 18 June 2026 to 24 June 2026.
The successful completion of PPB and NDA inspection marks a significant milestone in Concord Biotech’s global growth journey.
“This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint,” the company said in a statement.
Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide.
The company’s consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25.
The scrip rose 0.63% to currently trade at Rs 1296.80 on the BSE.
The company said, 'The successful completion of the ANVISA inspection marks a significant milestone in Concord Biotech's global growth journey. This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint. It also advances our international expansion strategy by enhancing access to one of the world's largest pharmaceutical markets and broadening the reach of our high-quality APIs across key geographies.'
The counter rose 0.30% to Rs 1,349.30 on the BSE.
According to market estimates, the US market size for Tofacitinib tablets across both strengths is approximately $500 million. The approval is expected to enable the company to tap this market opportunity, expand its product portfolio, and support its long-term growth strategy in the US and other international markets.